Collaborating for Cures Leveraging Global Public-Private Partnerships to Accelerate Biopharmaceuticals Development

Event Date: 03/07/2013

The Innovative Medicines Initiative (IMI) and Critical Path Institute (C-Path) held a joint event in Brussels, Belgium on the challenges and opportunities of public-private partnerships (PPPs). More than 120 participants attended the conference and many more followed the live webcast.

This first ever public conference co-sponsored by IMI and C-Path featured cross-sector participants discussing challenges and opportunities in the rapidly-evolving PPP space. The lively discussion focused on identifying mechanisms for enhancing the productivity of PPPs, coordinating individual PPP efforts to avoid duplication, and adopting best practices on data sharing, intellectual property, patient involvement in research, and other cross-cutting issues in order to streamline biopharmaceuticals development world-wide.

- Download the agenda
- Watch the entire conference online here
- Read the highlights of the event on twitter at #CollaboratingForCures

Presentations

Innovative solutions to shared challenges

**Introduction: Collaborating for Cures – Leveraging Global Public-Private Partnerships to Accelerate Biopharmaceuticals Development**
Michel Goldman, Executive Director, IMI Martha Brumfield, President and CEO, C-Path

**Harnessing the Discovery Engine of NIH to Maximize Translation**
Maria Freire, President, Foundation for the National Institutes of Health (FNIH)

**How Technology Transfer and other IP Agreements can Spur Bench to Bedside Translation**
Tania Bubela, Associate Professor, School of Public Health, University of Alberta

**How patients supply more than a voice in Accelerating Medical Product development**
Alastair Benbow, Chief Executive, The Age of the Brain

**How FDA Promotes Partnerships to Accelerate Medical Product Development**
ShaAvhree Buckman-Garner, Director, Office of Translational Sciences, CDER, FDA
IMI and C-Path collaboration on Alzheimer’s disease

**Prediction and Faster Assessment of Functional Properties of New Drug Candidates for Alzheimer’s Disease in Early Clinical Development: The IMI PharmaCog project**
Jill Richardson, EFPIA coordinator IMI PharmaCog / Director, External Alliances and Development, GSK R&D China

**European Medical Informatics Framework (EMIF)**
Simon Lovestone, Director Biomedical Research Centre for Mental Health and Dementia, King’s College London

**Coalition Against Major Diseases: Regulatory Science can Accelerate Drug Development for Neurodegeneration**
Diane Stephenson, Executive Director, Coalition Against Major Diseases, Critical Path Institute

**The Regulator’s View**
Maria Isaac, Scientific Advisor, European Medicines Agency

IMI and C-Path collaboration on tuberculosis

**PreDiCT-TB Model-based preclinical development of antituberculosis drug combinations**
Gerry Davies, Senior Lecturer in Infection pharmacology, University of Liverpool

**CPTR Mission, Structure & Goals for Innovation**
Debra Hanna, Executive Director, Critical Path to TB Drug Regimens